T he difference in pathophysiology between heart failure with a reduced ejection fraction (HFrEF) and heart failure with a preserved ejection fraction (HFpEF) remains poorly understood, and effective treatment options are currently not available for HFpEF. [1] [2] [3] [4] Therefore, a better understanding of the pathophysiology of HFpEF is required, which eventually may help to improve outcome. Patient-specific biomarker profiles are useful for the purpose of monitoring disease severity and progression, to guide therapy, but also for characterizing the pathophysiology of HF. [5] [6] [7] [8] [9] We hypothesize that differences in biomarker levels and correlative associations between HFrEF and HFpEF may provide important insights into specific activities of pathophysiological processes. [5] [6] [7] [8] [9] The aim of this study was to characterize HFpEF and HFrEF using a network analysis on an extensive set of 33 biomarkers of various pathophysiological pathways. Therefore, we investigated differences in biomarker levels, patterns of correlations, and predictive value of biomarkers in patients with HFpEF and HFrEF.
Methods Study Design and Population
Measurements of biomarkers were performed in a subcohort of the Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure (COACH) trial of which rationale, design, and results have been previously described. 10, 11 In short, the COACH trial studied the effects of additional intensive nurse-led support on the prognosis of 1023 chronic HF patients. A hospital admission for HF (NYHA II-IV) inclusion criteria for the COACH trial included and patients had to be at least 18 years of age. Patients were excluded if they underwent an intervention (percutaneous transluminal coronary angioplasty, coronary artery bypass graft, heart transplantation, valve replacement) in the previous 6 months or if they had a planned intervention in the following 3 months. Additionally, patients were excluded if they had an ongoing evaluation for heart transplantation. 10 Left ventricular ejection fraction (LVEF) measurements were available in 832 patients. Biomarkers were measured in blood collected from 460 patients shortly before discharge between 8:00 AM and 4:00 PM, after patients had been clinically stabilized and were considered well enough to go home. Baseline characteristics of the current substudy were comparable to the entire COACH study (Table S1 ). The study complies with the Declaration of Helsinki, local medical ethics committees approved the study, and all patients provided written informed consent.
Study and Laboratory Measurements
HFpEF was defined as having a LVEF ≥45%, measurements of high-sensitive C-reactive protein (hs-CRP), pentraxin-3, growth differentiation factor, soluble receptor of advanced glycation end-products, interleukin-6, tumor necrosis factor a, tumor necrosis factor-associated receptor 1 a, myeloperoxidase, syndecan-1, periostin, ST-2, osteopontin, pro-atrial-type natriuretic peptide (proANP), vascular endothelial growth factor receptor (VEGFR), angiogenin, end-terminal pro c-type natriuretic peptide, neuropilin-1, endothelial cell-selective adhesion molecule, neutrophil gelatinase-associated lipocalin, d-dimer, WAP 4-disulfide core domain protein HE4, mesothelin, polymeric immunoglobulin receptor, prosaposin, and TROY were measured by Alere San Diego, Inc, (San Diego, CA), using enzyme-linked immunosorbent assays. Immunoassays to ST2 were developed by Alere. This research assay by Alere has not been standardized to the commercialized assays used in research or in clinical use. Furthermore, the extent to which this Alere assay correlates with the commercial assay is not fully characterized. Galectin-3 was measured using ELISA by BG Medicine, Inc. (Waltham, MA). Transforming growth factorb and VEGF were analyzed using a quantitative multiplexed sandwich ELISA system, SearchLightw proteome arrays (Aushon BioSystems, Billerica, MA). N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured using the Elecsys proBNP ELISA by Roche Diagnostics (Mannheim, Germany). Erythropoietin a was measured using the IMMULITEw erythropoietin ELISA by Diagnostic Products Corporation (Los Angeles, CA). Inter-and intra-assay coefficients of the assays used can be found in Table S2 . Endothelin-1, interleukin-6, and cardiac-specific troponin I were measured in frozen plasma samples collected at baseline using highsensitive single molecule counting (SMC TM ) technology (RUO, Erennaâ Immunoassay System; Singulex Inc, Alameda, CA).
Estimated glomerular filtration rate was based on the simplified Modification of Diet in Renal Disease.
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Study End Points
For studying the relationship between biomarker levels and outcome, the primary end point of the COACH trial was used. This end point is a combined end point consisting of all-cause mortality and/or HF-related rehospitalizations at 18 months. An independent end point committee adjudicated the end point. Following this, a multivariable interaction test was performed correcting for the COACH risk engine. The COACH risk engine includes sex, age, pulse pressure, diastolic blood pressure, history of stroke, history of diabetes mellitus, estimated glomerular filtration rate, atrial fibrillation, myocardial infarction, peripheral arterial disease, and levels of NT-proBNP and sodium and is powered for the primary end point used in this study, as published elsewhere. 16 The relationship of the primary end point with biomarkers, showing a significant interaction HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IL-6, interleukin 6; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type natriuretic peptide; PSAP, prostatespecific acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2, suppression of tumorigenicity 2; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulfide core domain protein.
Statistical Analysis
with HF status and outcome, was then graphically depicted using Kaplan-Meier curves. To correct for potential optimism and given the limited sample size, we bootstrapped the estimates with 1000 iterations. 17 The significance of a difference between tertiles of biomarker levels and association with outcome was tested using the Log-rank test. Univariable and multivariable associations of biomarkers with outcome were tested using the Cox regression. Tests performed were 2-tailed and a P-value of <0.05 was considered statistically significant. All statistical analyses were performed using STATA version 13.0 (StataCorp LP, College Station, TX) and R, version 3.2.3.
Results
Patient Characteristics
The 460 patients in this cohort had a mean age of 70.6AE11.1 years and 37.4% were female. Most patients were in NYHA class III (52%) with a mean LVEF of 32.5AE14.0% (Table 1) . Ninety-six patients had HFpEF (21% Figure S1 ). Table 2 shows the baseline biomarker concentrations stratified according to HFrEF and HFpEF where P-values shown are corrected for multiple testing. Levels of hs-CRP were higher in HFpEF (3.6 mg/L versus 2.1 mg/L, P=0.001) and levels of pentraxin-3 were higher in HFrEF (3.9 ng/mL versus 3.2 ng/ mL, P=0.009). Levels of cardiac stretch markers NT-proBNP (2988 pg/mL versus 1948 pg/mL, P<0.001) and proANP (21.9 pg/mL versus 17.0 pg/mL) were higher in HFrEF. Additionally, the angiogenesis-specific marker VEGFR (0.8 ng/mL versus 0.7 ng/mL, P=0.009) was higher in HFrEF. After adjusting for multiple comparisons, levels of hs-CRP (P=0.022) remained significantly higher in HFpEF, while the cardiac stretch markers NT-proBNP (P<0.001) and proANP (P=0.042) remained significantly higher in HFrEF.
Biomarker associations with HFrEF and HFpEF are shown in Table S3 . When correcting for clinical covariates (age, sex, estimated glomerular filtration rate, systolic blood pressure, a history of myocardial infarction; diabetes mellitus; atrial fibrillation and anemia), higher levels of hs-CRP (odds ratio: 1.29; 95% CI 1.09-1.52, P=0.003) remained associated with HFpEF, while higher levels of NT-proBNP (odds ratio: 0.68; 95% CI 0.57-0.82, P<0.001) and proANP (odds ratio: 0.69; 95% CI 0.53-0.88, P=0.003) remained associated with HFrEF. After additionally correcting for b-blocker and angiotensinconverting enzyme inhibitor/angiotensin II receptor blocker use, the statistical associations for these 3 markers remained (Table S3) .
Biomarker Associations and Network Analysis
Heatmaps for the association between biomarkers in HFrEF and HFpEF are depicted in Figure 1 . Figure 2 shows the graphical depiction of biomarker networks in HFrEF and HFpEF. Results from the correlation analysis and associated heatmaps reveal that correlations between biomarkers in HFpEF are more associated with remodeling and inflammation, while in HFrEF angiogenesis is a more prominent feature (Figure 1 ). Network analysis further showed myeloperoxidase to be involved in interactions in both HFrEF and HFpEF.
Additionally, renal marker neutrophil gelatinase-associated lipocalin and blood urea nitrogen as well as inflammation marker receptor of advanced glycation end-products were involved in biomarker associations in HFpEF.
When examining the exclusive interactions between biomarkers in HFrEF and HFpEF, HFpEF revealed interactions, which were mainly associated with inflammation (interleukin-6; pentraxin-3; Table 3 , corrected P-value for difference <0.05). In contrast, HFrEF showed exclusive interactions that were NT-proBNP mediated ( Table 3 ), indicating that biomarker interactions are more associated with cardiac stretch in HFrEF and inflammation in HFpEF. In sensitivity analysis with a definition of HFrEF at LVEF ≤40% and a definition of HFpEF at LVEF ≥50%, exclusive associations in HFpEF remained inflammation mediated, while NT-proBNP mediated associations in HFrEF (Table S4 ).
Outcome
Of the total cohort, 41% reached the clinical end point of death and/or HF rehospitalization (41% HFrEF versus 44.8% HFpEF, P=0.659, Figure S2 ). NT-proBNP was found to be equally predictive in HFrEF and HFpEF (Table S5) . A significant interaction in both univariable and multivariable analysis was found for HF status and neuropilin as well as osteopontin (both P<0.05). Both biomarkers were found only to be predictive in HFpEF (Figures 3 and 4 , Table S5 ). Interaction between neuropilin (P=0.007) and osteopontin (P=0.018) and HF status for the primary end point remained following sensitivity analysis for a definition of HFpEF of LVEF ≥50%. After bootstrapping with 1000 iterations, the interaction with HF status for the primary end point stayed significant for both osteopontin (P=0.002) and neuropilin (P=0.011) in univariable analyses. Also in multivariable analyses, the interaction remained significant for osteopontin (P=0.016) and neuropilin (P=0.015).
When examining the relationship with HF rehospitalizations and all-cause mortality separately in univariable analysis, we see that osteopontin is predictive for both HF rehospitalizations (P=0.007) and all-cause mortality (P=0.031) separately, but not in HFrEF (Figures S3 and S4) . Neuropilin was predictive in univariable analysis for all-cause mortality in both HFrEF (P=0.003) and HFpEF (P=0.023). However, neuropilin was only predictive of HF rehospitalizations in HFpEF (P=0.026) and not in HFrEF (P=0.026) (Figures S5 and S6 ).
Discussion
In this study, we demonstrate a distinct biomarker profile for HFpEF and HFrEF patients by using a novel approach employing network analysis to identify exclusive interactions within the 2 disease entities. Higher levels of Hs-CRP and BUN indicates blood urea nitrogen; cTNI, cardiac troponin-I; EPOa, erythropoietin; ESAM, endothelial cell-selective adhesion molecule; ET-1, endothelin-1; GDF-15, growth differentiation factor 15; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection fraction; hs-CRP, high-sensitive C-reactive protein; IL-6, interleukin 6; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type natriuretic peptide; PSAP, prostate-specific acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2, suppression of tumorigenicity 2; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulfide core domain protein.
lower levels of cardiac stretch markers NT-proBNP and pro-ANP are found in HFpEF, which confirm previous studies. 8, 18 Furthermore, exclusive interactions between biomarkers in HFpEF were found to be associated with inflammation and angiogenesis. In contrast, HFrEF showed exclusive interactions associated with NT-proBNP. This is the first study reporting on exclusive interactions between biomarkers in HFrEF and HFpEF. Additionally, this study showed for the first time that angiogenesis marker neuropilin and remodeling marker osteopontin have exclusive predictive value for clinical outcome in HFpEF. Levels of hs-CRP were found to be higher in HFpEF patients compared to HFrEF patients. Overall, reports with regard to differences in association of CRP between HFrEF and HFpEF have lacked consensus. 8, [19] [20] [21] Yet, patients included in the previous studies were older and had relatively low levels of NT-proBNP. 8, 19, 20, 22 Regardless of the difference in levels, predictive value for hs-CRP was found to be limited in both HFrEF and HFpEF after correction for a risk model in both this and an earlier study. 21 The cardiac stretch markers proANP and NT-proBNP were found to be lower in HFpEF. This is the first study reporting differential levels of proANP in HFrEF and HFpEF. The difference in levels of NTproBNP between HFrEF and HFpEF confirms earlier reports. 8, 18, 23 A recent study used a similar network analysis approach. 8 However, the number of biomarkers studied was limited and no exclusive correlations were identified. When examining exclusive correlations in HFpEF and HFrEF between biomarkers, we identified correlations that were inflammation and angiogenesis associated in HFpEF, while correlations were associated with NT-proBNP in HFrEF. The relatively strong correlations between markers in both HFrEF and HFpEF provide putative insights into possible differences at the pathophysiological pathway level. For HFpEF, correlations were found to be associated with interleukin-6 and pentraxin-3. This is in line with earlier suggestions, in which a proinflammatory state was proposed to underlie the pathophysiology of HFpEF. [24] [25] [26] [27] [28] [29] In contrast, exclusive interactions in HFrEF were associated with NT-proBNP. As such, the pathophysiology of HFrEF seems to be more associated with cardiac stretch and oxidative stress. 24 However, using network analysis for determining underlying pathophysiological differences between disease entities using biomarkers is a relatively novel approach. Future studies should confirm GDF-15, growth differentiation factor 15; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IL-6, interleukin 6; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; NT-proCNP, amino terminal pro-C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; proANP, pro-atrial-type natriuretic peptide; PSAP, prostate-specific acid phosphatase; RAGE, receptor of advanced glycation end-products; ST-2, suppression of tumorigenicity 2; TGF-b, transforming growth factor b; TNF-a, tumor necrosis factor a; TNF-a-R1a, tumor necrosis factor a receptor 1a; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; WAP4C, WAP 4 disulfide core domain protein.
these findings as well as combine them with data from experimental studies to examine whether the pathophysiological relationships found in clinical data also translate to pathophysiological differences in an experimental setting. Furthermore, most biomarkers are not cardiac exclusive. 5 This makes it relatively difficult to discern whether biomarker differences found in a clinical study are the cause or consequence of HF. To optimize interpretability of biomarker studies, future studies should be focused on biomarkers that are highly cardiac specific. Secondly, when biomarker differences are found, experimental studies should validate the findings and discern possible underlying pathophysiological processes. This study also showed differential association with outcome of angiogenesis markers neuropilin and remodeling marker osteopontin, which were both found to be more predictive in HFpEF. Results with regard to differential association with outcome should be interpreted in an explanatory context of the pathophysiology, in which an increase in levels of a certain biomarker can be detrimental in 1 disease entity and not necessarily in the other through biological involvement or reflecting an underlying pathway. Indeed, osteopontin was reported earlier to be involved in prognosis in HF. 30 However, a differential involvement between HFrEF and HFpEF has not been previously reported.
Earlier experimental studies found a direct involvement of osteopontin and cardiac remodeling, which in turn was found to cause diastolic dysfunction. 31 Neuropilin is identified as a coreceptor of vascular endothelial growth factor receptor 2 (VEGFR-2). 32 In a murine model of cardiac pressure overload, animals that were heterozygous for neuropilin showed higher mortality rates. 33 This is the first study reporting the predictive value of neuropilin in HF for the combined end point. Here, we found EPO-A indicates erythropoietin; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart failure with a reduced ejection fraction; IL-6, interleukin 6; NGAL, neutrophil gelatinaseassociated lipocalin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; PSAP, prostate-specific acid phosphatase; VEGF, vascular endothelial growth factor. *Corrected P-value. † P-value lower than the significance treshhold of 0.05. Figure 3 . Kaplan-Meier curves depicting the relationship with outcome of osteopontin in tertiles, stratified to HFrEF and HFpEF. HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
that neuropilin was predictive of HF rehospitalizations in HFpEF. Additionally, in multivariable analysis, neuropilin only held predictive power in HFpEF. This suggests that neuropilin is more reflective of HF severity in HFpEF and not in HFrEF. Essentially, neuropilin is associated with angiogenesis. This again emphasizes the importance of angiogenesis markers in HFpEF compared to HFrEF. 24 In earlier studies a significant association between outcome and HF status was found for end-terminal pro c-type natriuretic peptide and galectin-3 with a definition of HFpEF of LVEF >40%. 34, 35 These findings were confirmed in this study.
Additionally, an earlier publication found significant predictive value of syndecan-1 in HFpEF but not in HFrEF. 6 The fact that no significant interaction was found in this study for syndecan-1 and the primary end point can potentially be explained by the limited power of this study for HFpEF patients at a definition of LVEF >45%, and the previous publication for syndecan-1 corrected for a stepwise based model for syndecan-1 instead of the COACH risk model. The clinical implications of this study are 2-fold. First, this study characterizes the underlying pathophysiology of patients with HFpEF to be associated with inflammation and endothelial function. This confirms earlier studies with regard to HFpEF and endorses the earlier proposed theory by Paulus et al. 24 Secondly, this study propagates a novel method for utilizing network analysis to analyze a wide array of biomarkers in discerning the underlying pathophysiology of disease entities in HF. 8 This methodology provides a possible step forward in dissecting the HF syndrome.
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Strengths and Limitations
The strengths of this study are the relatively high levels of NTproBNP of both the HFrEF and HFpEF patients and the large number of available biomarkers. By having relatively high NTproBNP levels, the HFpEF patients in this study represent true HF patients and have a relatively low number of false positives. Secondly, the large number of biomarkers from different disease domains available in this study provide for a more unbiased approach towards discerning underlying pathophysiological pathways. However, the current analysis is a post-hoc analysis, leading to a possible selection bias. Secondly, since patients included are of European descent and relatively old, this limits extrapolation to patients of different age and origin. Also, pharmacological treatment during hospitalization might have influenced biomarker levels and associations between HFrEF and HFpEF. Furthermore, the choice for biomarkers was restricted by limited baseline sample availability, with the result that several interesting markers could not be studied. Therefore, this study is not an exhaustive study of biomarkerlevel differences in HFrEF and HFpEF and should be considered exploratory and hypothesis generating. Also, some of the biomarkers measured had relatively high coefficients of variation. Therefore, some possible interesting interactions and differences between biomarkers in HFrEF and HFpEF may have been missed. Most importantly, results from this study should be validated in a separate cohort.
The sampling of patients in COACH was performed at discharge after recompensation. Since no data are available on treatment during admission for HF previous to discharge, this might confound some of the reported findings. In this context, patients in the COACH trial cover a gray area between acute decompensated and chronic HF patients. The findings in this study should be regarded as explanatory in the context of the pathophysiology of HFpEF and HFrEF, acting as a stepping-stone for further research.
Conclusions
Biomarker levels differ in HFpEF and HFrEF, mainly in the domains of cardiac stretch and inflammation. Interactions in Figure 4 . Kaplan-Meier curves depicting the relationship with outcome of neuropilin in tertiles, stratified to HFrEF and HFpEF. HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
HFpEF were found to be associated with inflammation and angiogenesis, while interactions in HFrEF were associated with cardiac stretch. The angiogenesis marker neuropilin and remodeling marker osteopontin were found to only hold predictive value in HFpEF, possibly reflecting underlying pathophysiological processes. Results of this study should be confirmed in prospective biomarker studies.
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